<DOC>
	<DOCNO>NCT01968317</DOCNO>
	<brief_summary>The purpose study see megestrol acetate plus metformin effective return endometrial tissue normal state megestrol acetate alone patient endometrial atypical hyperplasia early stage endometrial adenocarcinoma .</brief_summary>
	<brief_title>Megestrol Acetate Plus Metformin Megestrol Acetate Patients With Endometrial Atypical Hyperplasia Early Stage Endometrial Adenocarcinoma</brief_title>
	<detailed_description>After diagnose endometrial atypical hyperplasia ( EAH ) type I endometrial cancer ( EC ) dilatation curettage ( D &amp; C ) hysteroscopy , patient enrol . Age , waist circumstance , blood pressure , basic history infertility , blood pressure , serum lipid level side effect collect . Blood test , include triglyceride , high density lipoprotein-cholesterol , fast blood glucose , liver kidney function perform treatment evacuate metabolic condition . Patients randomize 1 2 treatment group . Patients receive metformin 500 mg mouth third daily megestrol acetate 160 mg mouth daily 3 month Arm I . Patients receive megestrol acetate 160 mg PO daily 3 month Arm II . Then hysteroscope use evaluate endometrial condition , finding record . For patient EAH , complete response ( CR ) define reversion endometrial atypical hyperplasia proliferative secretory endometrium ; partial response ( PR ) define regression simple complex hyperplasia without atypia ; response ( NR ) define persistence disease ; progressive disease ( PD ) define appearance endometrial cancer patient . EAH treatment define PR patient EC . Continuous therapy need PR , NR PD . After completion study treatment , 3 month maintenance treatment recommend patient CR , follow 2 year . In addition , 've already pilot study 19 patient primarily diagnose endometrial atypical hyperplasia August 2012 April 2013 . 10 patient Arm I 9 patient Arm II . Metabolic syndrome evaluate among subject . After treatment , megestrol acetate plus metformin work well megestrol acetate alone . But two arm show difference NR patient , may suggest metformin worked antitumor drug insulin sensitizer . More supportive research need verify .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Be age 1845 year old Primarily confirm diagnosis endometrial atypical hyperplasia base upon D &amp; C hysteroscopy OR primarily confirm diagnosis endometrial adenocarcinoma ( G1 , low tumor grade ) , base upon D &amp; C hysteroscopy , three MRI parameter show 's myometrial invasion , extension beyond corpus , enlarge lymph node Have desire remain reproductive function uterus Need able undergo correlative treatment followup Have history serious liver renal dysfunction Have confirm diagnosis malignant tumor genital system Have take oral contraceptive medicine treatment endometrial hyperplasia past 6 month Ask removal uterus conservative treatment serum CA125 &gt; 35 Um/L</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Endometrial Atypical Hyperplasia</keyword>
	<keyword>Endometrial Adenocarcinoma</keyword>
	<keyword>Conservative Medication</keyword>
</DOC>